Results: AI1008 demonstrated remarkable potency against the purified abl kinase by inhibiting enzyme activity at low nanomolar concentrations (IC_{50} = 3.1 nM). Additionally, the compound caused a significant reduction in viability of K652 cells (IC_{50} = 1.3 nM). Pharmacokinetic studies in female Balb/c mice indicated good oral absorption of AI1008 with a C_{max} value of 1.6 μM. Further, the compound had an elimination half-life of 1.5 hr with a clearance value of 26.9 ml/min/kg.
Conclusions: Our results demonstrate that AI1008 is a potent abl-kinase inhibitor with a favourable pharmacokinetic profile and comparable IC_{50} values to existing abl-kinase inhibitors. AI1008 is currently being tested for *in vitro* and *in vivo* efficacy across various cancer cell lines and selectivity against other receptor tyrosine kinases. Besides CML, xenograft models of gastrointestinal stromal tumors are currently underway to evaluate the efficacy of AI1008.

345 POSTER

Preclinical profile of novel, potent, and selective PI3 kinase delta inhibitors

S. Viswanadha[1], M.P. Muthuppalaniappan[2], K.V.V.S. Varanasi[3], G. Babu[2], R.R. Lekkala[1], S. Veeraraghavan[3], S. Vakkalanka[4]. *[1]Incozen Therapeutics Pvt. Ltd, Biological Research, Hyderabad Andhra Pradesh, India; [2]Incozen Therapeutics Pvt. Ltd, Medicinal Chemistry, Hyderabad Andhra Pradesh, India; [3]Incozen Therapeutics Pvt. Ltd, Pharmacokinetics, Hyderabad Andhra Pradesh, India; [4]Incozen Therapeutics Pvt. Ltd, General Management, Hyderabad Andhra Pradesh, India*

Background: Phosphoinositide-3 kinase (PI3K) belongs to a class of intracellular lipid kinases that phosphorylate the 3 position hydroxyl group of the inositol ring of phosphotidylinositol. The PI3K pathway is frequently activated in human cancers and thus represents an attractive target for small molecule inhibitors. Pan-PI3K inhibitors currently in development have been associated with adverse side-effects such as insulin resistance, thus necessitating the need to develop isoform specific inhibitors of PI3K. Herein, we describe the biological and pharmacokinetic properties of representative molecules from a series of novel and small molecule PI3Kδ inhibitors with scope to be further developed as clinical candidates for hematological malignancies such as acute myeloid and lymphoblastic leukemias.
Methods: Activity of test compounds on individual PI3K isoforms was determined by a Homogenous Time Resolved Fluorescence assay (Millipore, Billerica, MA) with modifications. Cell viability assay was conducted to determine the growth inhibitory effect of the compounds on the high PI3Kδ expressing THP-1 cell line. Inhibition of Akt phosphorylation was determined by Western blotting using monoclonal antibodies (Cell Signaling Technology, Beverly, MA) directed against the Ser473 and Thr308 residues. CYP inhibition potential of the compounds was evaluated in human liver microsomes.
Results: Among the compounds evaluated, RP5057, RP5066 and RP5067 inhibited PI3Kδ with IC_{50} values of 11.2, 7.4, and 23.3 nM respectively. Besides, the compounds displayed a high degree of selectivity over the alpha (>170–400 fold), beta (>40–120 fold), and gamma (>100–500 fold) isoforms. In addition, the compounds caused a dose-dependent reduction in viability of THP-1 cells. While total Akt remained unaffected, the compounds caused a significant reduction in phosphorylation at both the Ser473 and Thr308 sites. Further, the compounds showed no significant CYP inhibition in human liver microsomes.
Conclusions: Results demonstrate the PI3K delta selective nature of RP5057, RP5066, and 5067 along with an ability to suppress proliferation of cancer cells. *In vitro* selectivity and potency data indicate the therapeutic potential of the compounds in hematological cancers without the deleterious effects commonly associated with the Pan PI3K inhibitors. The compounds are currently being tested for *in vitro* and *in vivo* efficacy across various cancer cell lines and xenograft models besides selectivity against other kinases.

346 POSTER

Activated RON tyrosine kinase drives cellular proliferation, migration and invasion with corresponding tumor growth and metastasis in mice

M.R. Albertella[1], Y. Peng[1], S. McCormack[1], J. Kahler[1], S. Thomson[2], D. Landfair[3], P.C. Gokhale[3], J.E. Bugaj[3], R. Wild[3], J. Pachter[1]. *[1]OSI Pharmaceuticals, Biochemical and Cellular Pharmacology, Farmingdale NY, USA; [2]OSI Pharmaceuticals, Translational Research, Farmingdale NY, USA; [3]OSI Pharmaceuticals, In Vivo Pharmacology, Boulder CO, USA*

The receptor tyrosine kinase RON (MST1R) is closely related to cMet, but its role in cancer biology remains as yet poorly defined. Activating mutations of RON appear to be rare in human cancer, hence autocrine or paracrine stimulation by its unique ligand MSP (macrophage stimulating protein) are likely to be required to drive its tumorigenic activity *in vivo*. Since murine MSP does not bind to human RON, most human xenografts lacking MSP expression do not activate RON in mouse models, and thus the effect of RON signaling on tumour growth has likely been underestimated in murine xenograft models. We developed an engineered tumour model that can be driven by RON in the absence of a functional MSP signal, which was used to characterize the effects of RON activity *in vitro* and *in vivo*. NIH3T3 cells were retrovirally transfected with a constitutively active form of the human RON kinase to derive stable clones (termed 3T3 caRON) which were extensively characterized for signaling and phenotypic effects.
3T3 caRON cells show strong constitutive phosphorylation of RON *in vitro*, with concomitant activation of pAKT and pERK. This phosphorylation can be further increased by MSP, demonstrating a substantial, although incomplete, activation of RON in these cells. 3T3 caRON cells show enhanced migration, invasion, proliferation and anchorage-independent growth compared to the parental NIH3T3 cells, these effects being further stimulated by the addition of MSP. Similar signaling and oncogenic phenotypes were observed after MSP-stimulation of non-engineered tumour cell lines, demonstrating that the 3T3 caRON cells recapitulate bona fide RON-dependent activities. Importantly, 3T3 caRON cells grow aggressively as tumour xenografts and metastases in mice, whereas parental NIH3T3 cells are not tumorigenic, demonstrating that activated RON is required for tumour growth in this model.
In conclusion, 3T3 caRON cells can be used to model the consequences of RON activation and effects of RON-directed therapeutic intervention in RON-dependent tumours in mice *in vivo*, which has not previously been possible due to the inability of mouse MSP to activate human RON.

347 POSTER

Blockade of fatty acid synthase causes ubiquitination and degradation of PI3K effector proteins in ovarian cancer

T.W. Grunt[1], H. Karlic[2], R. Wagner[1], C.F. Singer[3], F. Varga[4], K. Tomek[1]. *[1]Medical University Vienna, Department of Medicine I, Vienna, Austria; [2]Medical University Vienna, Ludwig Boltzmann Cluster Oncology, Vienna, Austria; [3]Medical University Vienna, Department of Obstetrics/Gynecology, Vienna, Austria; [4]Hanusch Hospital, Ludwig Boltzmann Institute of Osteology, Vienna, Austria*

Phosphatidylinositol-3 kinase (PI3K) controls proliferation, differentiation, tumorigenesis, and apoptosis. Many ovarian carcinomas harbor aberrations within this pathway. The PI3K target AKT phosphorylates mTOR. mTOR activates S6 via p70S6K. S6 is involved in translation control. mTOR also phosphorylates eukaryotic translation initiation factor 4E (eIF4E) inhibitor binding protein 1 (4EBP1), which also controls translation. In addition, many ovarian carcinomas harbor aberrations of the ErbB1 or -2 receptor. Although PI3K transmits ErbB-derived signals and stimulates cancer growth clinical studies yet reveal that ErbB1 or -2 drugs are largely inefficient in ovarian carcinoma. Therefore, novel targeting strategies are urgently needed. Fatty acid synthase (FASN) being overexpressed in ~80% of ovarian tumors is a marker for poor prognosis. It supports formation of membrane lipid rafts, which accommodate growth factor receptors incl. ErbBs. FASN thus facilitates signal generation and inhibition of FASN delays ovarian cancer progression. We reported that the FASN inhibitor C75 downregulates ErbB1 and -2 in ovarian cancer and sensitizes the cells against ErbB drugs (Grunt et al., BBRC, 385, 454). We now show that C75 abrogates A2780 ovarian cancer cell growth. This correlates with reduced phosphorylation of AKT, mTOR, p70S6K and 4EBP1 in Western blots caused by specific deactivation and by ubiquitin-mediated degradation of these PI3K effectors. In contrast, specific activation of the mitogen-activated protein kinase ERK1/2 is increased, although ERK1/2 steady-state levels are concurrently decreased by C75. In comparison, the PI3K inhibitor LY294002 blocks phosphorylation while concurrently upregulating steady-state levels of AKT, mTOR, p70S6K, and 4EBP1, and it activates ERK1/2. This suggests that PI3K/AKT cross-inhibits ERK1/2, which is abrogated by PI3K/AKT silencing, and that PI3K, but not ERK1/2, is crucial for growth arrest of ovarian cancer cells. We demonstrate for the first time that C75-mediated silencing of PI3K reduces phosphorylation and protein stability by increasing ubiquitination. Thus, C75 provides additive anticancer action, when compared to the LY294002, which directly targets PI3K and downstream signaling, but does not stimulate protein degradation. In summary, FASN is a promising drug target, which should be further developed for use in ovarian carcinoma.
Supported by 'Medical Scientific Fund of the Mayor of the City of Vienna' (#08037).